Donia Moujalled
Monash University
H-index: 18
Oceania-Australia
Top articles of Donia Moujalled
BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms
Blood
2023/11/28
Donia Moujalled
H-Index: 12
Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
2023/5/18
The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
Cell Death & Differentiation
2023/4
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
Blood
2023/2/9
COMBINACIÓN DE UN INHIBIDOR DE BCL-2 Y UN INHIBIDOR DE MCL1, USOS Y COMPOSICIONES FARMACÉUTICAS DE ESTOS (Divisional del Expediente 2019-0022)
2022/10/27
Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
2022/10/11
Combination of mcl-1 inhibitor and standard of care treatment for hematologic cancers, uses and associated pharmaceutical compositions
2022/2/25
Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro …
Blood
2021/11/23
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Blood, The Journal of the American Society of Hematology
2021/5/20
Donia Moujalled
H-Index: 12
Sarah Macraild
H-Index: 10
Maoshan Chen
H-Index: 21
Catherine Chang
H-Index: 26
Zhen Xu
H-Index: 3
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
Blood Advances
2020/10/27
combinação de um inibidor de mcl-1 e um tratamento com padrão de atendimento para cânceres hematológicos, seus usos e composições farmacêuticas
2020/7/7
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
Blood advances
2020/6/23
Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers hématologiques, utilisations et compositions pharmaceutiques associées
2020/4/29
Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico, usos y composiciones farmacéuticas de esta
2020/2/28
